Clinical evaluations at 90days confirmed that the primary objective of safety and tolerability wasachieved. In the Phase II study, conducted at 11 sites in 4 countries, 24 lung transplantpatients with confirmed RSV infection were randomized to receive inhaledALN-RSV01 (N=16) or placebo (N=8) once daily for three consecutive days.Overall, the study achieved its primary objective of demonstrating safety andtolerability of ALN-RSV01. (Nasdaq: CBST), an acute care focusedtherapeutics company, today reported complete data from their Phase II study ofALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus(RSV) infection. & LEXINGTON, Mass.–(Business Wire)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeuticscompany, and Cubist Pharmaceuticals, Inc.

HalliburtonVice President, Investor RelationsChristian Garcia, 713-759-2688orDirector, Corporate AffairsCathy Mann, 713-759-2605 Copyright Business Wire 2009. – 90 Day Data Confirm ALN-RSV01 Meets Primary Study Objective of Safety andTolerability -CAMBRIDGE, Mass. Adjusted increase in cash and equivalents (cash flow) for the second quarter of 2009 is calculated as: “As reported decrease in cash and equivalents (cash flow) for the second quarter of 2009″ less “As reportedpurchases of investments in marketable securities.”(b)As reported decrease in cash and equivalents (cash flow) for the second quarter of 2009 is calculated as the change in cash and equivalents from March 31, 2009 to June 30, 2009. Upon adopting FSP APB 14-1, the provisions were retroactively applied. The adjustment removes these purchases of investments in marketable securities.

51,” the provisions of which, among others, requires the recognition of noncontrolling interest (previously referred to as minority interest) as equity in the condensed consolidated balance sheets All periods presented have been restated. 160 “Noncontrolling Interests in Consolidated Financial Statements – an amendment of ARB No. All prior periods` basic and diluted earnings per share were restated. Upon adoption, both basic and diluted income per share for the six months ended June 30, 2008 decreased by $0.01 for continuing operations and net income. All periods presented have beenrestated.(e)On January 1, 2009, Halliburton adopted FSP Emerging Issues Task Force (EITF) 03-6-1, “Determining Whether Instruments Granted in Share-Based Payment Transactions AreParticipating Securities,” which provides that unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents, whether paidor unpaid, are participating securities and shall be included in the computation of both basic and diluted earnings per share. 160 “Noncontrolling Interests in Consolidated Financial Statements – anamendment of ARB No.

51,” the provisions of which, among others, requires the recognition of noncontrolling interest (previously referred to as minority interest) as equity in the condensed consolidated balance sheets and a revised presentation of the condensed consolidated statements of operations. upon separation.(d)On January 1, 2009, Halliburton adopted Statement of Financial Accounting Standards (SFAS) No. As a result, $7 million of additional non-cash interest expense was recorded in the six months ended June 30, 2008. (c)Loss from discontinued operations, net, in the six months ended June 30, 2008 included additional charges totaling $117 million, net of tax, related to adjustments to the indemnities and guarantees provided to KBR, Inc.